Compare RRC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRC | PRAX |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.6B |
| IPO Year | 1996 | 2020 |
| Metric | RRC | PRAX |
|---|---|---|
| Price | $41.92 | $317.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 15 |
| Target Price | $43.33 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 3.2M | 338.2K |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 151.38 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $3,115,515,000.00 | N/A |
| Revenue This Year | $14.43 | N/A |
| Revenue Next Year | $10.53 | $6,395.88 |
| P/E Ratio | $15.31 | ★ N/A |
| Revenue Growth | ★ 28.90 | N/A |
| 52 Week Low | $32.08 | $28.79 |
| 52 Week High | $48.31 | $354.87 |
| Indicator | RRC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 53.48 |
| Support Level | $34.07 | $282.49 |
| Resistance Level | $43.50 | $327.65 |
| Average True Range (ATR) | 1.56 | 17.83 |
| MACD | -0.60 | 2.26 |
| Stochastic Oscillator | 10.10 | 67.57 |
Range Resources is an exploration and production firm whose operations represent a pure play in the Marcellus shale, located in the Appalachian region of Southwest Pennsylvania. The company went public as Lomak Petroleum in 1980 and later reorganized as Range Resources in 1998. After an expensive 10-year venture with a multi-basin strategy, Range Resources found its identity as an Appalachian natural gas producer, offloading its Permian assets in 2013. Range quickly became a leading US gas producer after its merger with Memorial Resource Development in 2016. Following the merger, Range saw its operational unit costs rise to an uncompetitive level and subsequently sold the assets in 2020 to return to its roots as an Appalachian producer.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.